Carbon-carbon composites: Emerging materials for hypersonic flight

An emerging class of high temperature materials called carbon-carbon composites are being developed to help make advanced aerospace flight become a reality. Because of the high temperature strength and low density of carbon-carbon composites, aerospace engineers would like to use these materials in even more advanced applications. One application of considerable interest is as the structure of the aerospace vehicle itself rather than simply as a protective heat shield as on Space Shuttle. But suitable forms of these materials have yet to be developed. If this development can be successfully accomplished, advanced aerospace vehicles such as the National Aero-Space Plane (NASP) and other hypersonic vehicles will be closer to becoming a reality. A brief definition is given of C-C composites. Fabrication problems and oxidation protection concepts are examined. Applications of C-C composites in the Space Shuttle and in advanced hypersonic vehicles as well as other applications are briefly discussed

Interference of oxygen, carbon dioxide, and water vapor on the analysis for oxides of nitrogen by chemiluminescence

The interference of small concentrations (less than 4 percent by volume) of oxygen, carbon dioxide, and water vapor on the analysis for oxides of nitrogen by chemiluminescence was measured. The sample gas consisted primarily of nitrogen, with less than 100 parts per million concentration of nitric oxide, and with small concentrations of oxygen, carbon dioxide, and water vapor added. Results obtained under these conditions indicate that although oxygen does not measurably affect the analysis for nitric oxide, the presence of carbon dioxide and water vapor causes the indicated nitric oxide concentration to be too low. An interference factor - defined as the percentage change in indicated nitric oxide concentration (relative to the true nitric oxide concentration) divided by the percent interfering gas present - was determined for carbon dioxide to be -0.60 + or - 0.04 and for water vapor to be -2.1 + or - 0.3

High pressure flame system for pollution studies with results for methane-air diffusion flames

A high pressure flame system was designed and constructed for studying nitrogen oxide formation in fuel air combustion. Its advantages and limitations were demonstrated by tests with a confined laminar methane air diffusion flame over the pressure range from 1 to 50 atm. The methane issued from a 3.06 mm diameter port concentrically into a stream of air contained within a 20.5 mm diameter chimney. As the combustion pressure is increased, the flame changes in shape from wide and convex to slender and concave, and there is a marked increase in the amount of luminous carbon. The height of the flame changes only moderately with pressure

Pollutant emissions from flat-flame burners at high pressures

Maximum flame temperatures and pollutant emission measurements for NOx, CO, and UHC (unburned hydrocarbons) are reported for premixed methane air flat flames at constant total mass flow rate over the pressure range from 1.9 to 30 atm and for equivalence ratios from 0.84 to 1.12. For any given pressure, maxima typically occur in both the temperature and NOx emissions curves slightly to the lean side of stoichiometric conditions. The UHC emissions show minima at roughly the same equivalence ratios. The CO emissions, however, increase continually with increasing equivalence ratio. Flame temperature and NOx emissions decrease with increasing pressure, while the opposite is true for the CO and UHC emissions. The NOx data correlate reasonably well as a function of flame temperature only. Four flameholders, differing only slightly, were used. In general, the temperature and emissions data from these four flameholders are similar, but some differences also exist. These differences appear to be related to minor variations in the condition of the flameholder surfaces

Some materials perspectives for space transportation systems

The topics addressed are: personal background in entry systems; and common needs for space transportation vehicles - passive thermal protection systems; and an aerobrake concept

Recent advances in carbon-carbon substrate technology at NASA. Langley Research Center

A comparison of specific strengths of candidate high-temperature materials as a function of temperature is shown. From this comparison, it is apparent why there is an interest in carbon-carbon composites for applications as a strong, light-weight thermal protection system (TPS), or as hot structure, for applications above 2500 F. The lower bound of the carbon-carbon band is representative of the tensile strength of cross-ply Advanced Carbon-Carbon (ACC). The upper bound represents capabilities of various experimental carbon-carbon composites. Thin carbon-carbon composites, such as would be used as TPS panels or hot aero-structure, are usually constructed of layups of 2-D fabrics of carbon-fiber yarns (tows). Although the in-plane strengths of these composites can be very attractive, a major problem area is low interlaminar strength. The low interlaminar strength is the result of a relatively weak carbon matrix and poor interaction between the fibers and matrix. The purpose of this paper is to discuss strategies being employed to improve the interlaminar strengths of the materials at the upper bound of the carbon-carbon band, and to present some recent encouraging results. The emphasis of these strategies is to improve interlaminar shear and tensile strengths while maintaining, or even improving, the inplane properties

Four advances in carbon-carbon materials technology

Carbon-carbon composites are a specialty class of materials having many unique properties making these composites attractive for a variety of demanding engineering applications. Chief among these properties are exceptional retention of mechanical properties at temperatures as high as 4000 F, excellent creep resistance, and low density (1.6 to 1.8 g/cu cm). Although carbon-carbon composites are currently in service in a variety of applications, much development work remains to be accomplished before these materials can be considered to be fully mature, realizing their full potential. Four recent technology advances holding particular promise for overcoming current barriers to the wide-spread commercialization of carbon-carbon composites are described. These advances are: markedly improved interlaminar strengths (more than doubled) of two dimensional composites achieved by whiskerization of the fabric reinforcing plies, simultaneously improved oxidation resistance and mechanical properties achieved by the incorporation of matrix-phase oxidation inhibitors based on carborane chemistry, improved oxidation resistance achieved by compositionally graded oxidation protective coatings, and markedly reduced processing times (hours as opposed to weeks or months) accomplished through a novel process of carbon infiltration and coatings deposition based on the use of liquid-phase precursor materials

Class III β-tubulin expression as a predictor of docetaxel-resistance in metastatic castration-resistant prostate cancer

About half of the patients treated with docetaxel in the setting of metastatic castration-resistant prostate cancer (CRPC) are non-responders. Therefore, a marker of response would be beneficial for clinical decision-making. We evaluated class III β-tubulin (βIII-tubulin) expression as a predictor of resistance in this setting, which previously has been correlated with lack of response to taxanes in other cancers. Patients with CRPC were included if they were treated with at least 3 cycles of docetaxel between 1990 and 2011. βIII-tubulin expression was assessed by immunostaining, which was performed in tissue samples obtained either via biopsy or prostatectomy at the time of diagnosis. Rates of prostate-specific antigen (PSA) response and overall survival (OS) following docetaxel treatment were compared between patients with high (2+ or 3+ staining) vs. low (0 or 1+ staining) βIII-tubulin expression. Of 73 patients, 26 (35%) had a high expression of βIII-tubulin. A PSA decline of 10% or greater occurred in 65% of patients with a high βIII-tubulin expression vs. 89% with a low βIII-tubulin expression (p = 0.0267). The median OS for patients with a high βIII-tubulin expression was 17.4 (95% CI 8.7-21.0) months vs. 19.8 (95% CI 16.6-23.6) months for patients with a low expression (p = 0.039). Our results show that a high βIII-tubulin expression is a negative prognostic factor in metastatic CRPC patients treated with docetaxel

Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks?

In this review, we explore the concept of ‘double diabetes’, a combination of type 1 diabetes with features of insulin resistance and type 2 diabetes. After considering whether double diabetes is a useful concept, we discuss potential mechanisms of increased insulin resistance in type 1 diabetes before examining the extent to which double diabetes might increase the risk of cardiovascular disease (CVD). We then go on to consider the proposal that weight gain from intensive insulin regimens may be associated with increased CV risk factors in some patients with type 1 diabetes, and explore the complex relationships between weight gain, insulin resistance, glycaemic control and CV outcome. Important comparisons and contrasts between type 1 diabetes and type 2 diabetes are highlighted in terms of hepatic fat, fat partitioning and lipid profile, and how these may differ between type 1 diabetic patients with and without double diabetes. In so doing, we hope this work will stimulate much-needed research in this area and an improvement in clinical practice

Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapy

BACKGROUND: Epidermal growth factor receptor (EGFR) activation is associated with increased production of interleukin 6 (IL6), which is intensified by radiotherapy (RT) induced inflammatory response. Elevated IL6 levels intensifies RT-induced anemia by upregulating hepcidin causing functional iron deficiency. Cetuximab, an EGFR inhibitor, has been associated with lower rates of anemia for locally advanced head and neck squamous cell carcinoma (HNSCC). We hypothesized that concomitant cetuximab could prevent RT-induced anemia. METHODS: We queried our institutional head and neck cancers database for non-metastatic HNSCC cases that received RT with concomitant cetuximab or RT-only between 2006 and 2018. Cetuximab was administered for some high-risk cases medically unfit for platinum agents per multidisciplinary team evaluation. We only included patients who had at least one complete blood count in the 4 months preceding and after RT. We compared the prevalence of anemia (defined as hemoglobin (Hb) below 12 g/dL in females and 13 g/dL in males) and mean Hb levels at baseline and after RT. Improvement of anemia/Hb (resolution of baseline anemia and/or an increase of baseline Hb ≥1 g/dL after RT), and overall survival (OS) in relation to anemia/Hb dynamics were also compared. RESULTS: A total of 171 patients were identified equally distributed between cetuximab-plus-RT and RT-only groups. The cetuximab-plus-RT group had more locally-advanced stage, oropharyngeal and high grade tumors (p \u3c 0.001 for all). Baseline anemia/Hb were similar, however anemia after RT conclusion was higher in the cetuximab-plus-RT vs RT-only (63.5% vs. 44.2%; p = 0.017), with a mean Hb of 11.98 g/dL vs. 12.9 g/dL; p = 0.003, for both respectively. This contributed to significantly worse anemia/Hb improvement for cetuximab-plus-RT (18.8% vs. 37.2%; p = 0.007). This effect was maintained after adjusting for other factors in multivariate analysis. The prevalence of iron, vitamin-B12 and folate deficiencies; and chronic kidney disease, was non-different. Baseline anemia was associated with worse OS (p = 0.0052) for the whole study cohort. Nevertheless, improvement of anemia/Hb was only marginally associated with better OS (p = 0.068). CONCLUSIONS: In contrast to previous studies, cetuximab was not associated with lower rates of anemia after RT for nonmetastatic HNSCC patients compared to RT-alone. Dedicated prospective studies are needed to elucidate the effect of cetuximab on RT-induced anemia